For additional information about the RevAssist® program, please contact the Celgene Customer Care Center at 1-888-423-5436

About the REVLIMID REMS™ program

REVLIMID® (lenalidomide) is indicated for the treatment of patients with multiple myeloma (MM).

REVLIMID in combination with dexamethasone is indicated for the treatment of patients with MM who have received at least one prior therapy.

REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or
intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

To avoid embryo-fetal exposure, REVLIMID is only available under a restricted distribution program called "REVLIMID Risk Evaluation and Mitigation Strategy (REMS)™" (formerly known as the RevAssist® program). Only certified prescribers can prescribe REVLIMID and only certified pharmacies can dispense REVLIMID in the REVLIMID REMS™ program.

In order to receive REVLIMID, all patients must be enrolled in the REVLIMID REMS™ program and agree to comply with the requirements of the REVLIMID REMS™ program.

Key points of the REVLIMID REMS™ program

Prescriber

  • The prescriber enrolls and becomes certified with Celgene for the REVLIMID REMS™ program

  • The prescriber counsels patient on benefits and risks of REVLIMID

  • The prescriber provides contraception and emergency contraception counseling

  • The prescriber verifies negative pregnancy test for all female patients of reproductive potential

  • The prescriber completes a REVLIMID® (lenalidomide) Patient-Physician Agreement Form with each patient and sends to Celgene

  • The prescriber/patient completes applicable mandatory confidential survey

  • The prescriber obtains an authorization number from Celgene and writes it on every prescription, along with
    the patient risk category

  • The prescriber writes no more than a 4-week (28-day) supply, with no automatic refills or telephone prescriptions

  • The prescriber sends REVLIMID prescription to certified pharmacy

Pharmacy

  • The pharmacy certifies with Celgene for the REVLIMID REMS™ program

  • The certified pharmacy must obtain a confirmation number from Celgene before dispensing

  • The certified pharmacy counsels the patient, and completes an Education and Counseling Checklist

  • The certified pharmacy dispenses REVLIMID to patient along with a Medication Guide